Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Ammonia Solution, Strong. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CCR1 | P32246 | 1/20 | 0.46 |
| ▸ | CCR5 | P51681 | 1/20 | 0.46 |
| ▸ | CCR8 | P51685 | 1/20 | 0.46 |
| ▸ | METAP1 | P53582 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.46 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | NOS3 | P29474 | 2/20 | 0.42 |
| ▸ | NOS1 | P29475 | 2/20 | 0.42 |
| ▸ | NOS2 | P35228 | 2/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29419972 | 0.97 | — | — | |
| Ammonia Solution, Strong SCHEMBL264627 | 0.97 | — | — | |
| Ethane SCHEMBL28271620 | 0.94 | GRM5 (0.47) | GRM5KDM4ELMNACYP1A2POLB | |
| Bromide SCHEMBL28173480 | 0.94 | — | — | |
| Ammonia Solution, Strong SCHEMBL28211024 | 0.94 | — | — | |
| Hydrochloric Acid SCHEMBL29639694 | 0.94 | — | — | |
| SCHEMBL29599136 | 0.94 | KDM4E (0.50) | GRM5KDM4ELMNACYP1A2POLB | |
| SCHEMBL16322907 | 0.94 | KDM4E (0.50) | GRM5KDM4ELMNACYP1A2POLB | |
| SCHEMBL29472848 | 0.94 | — | — | |
| SCHEMBL2684 | 0.94 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 8630 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12629364-B2 | Methods of treating cancers overexpressing CARM1 with EZH2 inhibitors and platinum-based antineoplastic drugs | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2026-05-19 | — | — | US | claimed |
| EP-4729063-A2 | TREATMENT OF CANCER USING COENZYME Q10 COMBINATION THERAPIES | BPGbio, Inc. (US) | 2026-04-22 | — | — | EP | claimed |
| US-12601742-B2 | Methods and materials for treating endometrial cancer by assessing combinations of mutations and expression levels | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2026-04-14 | — | — | US | claimed |
| US-20260085120-A1 | Carrier-PD-L1 Binding Agent Compositions for Treating Cancers | MAYO FOUND MEDICAL EDUCATION & RES (US) | 2026-03-26 | — | — | US | claimed |
| US-20260069697-A1 | METHOD OF TREATING CANCER | INTENSITY THERAPEUTICS INC (US) | 2026-03-12 | — | — | US | claimed |
| WO-2026043617-A1 | COMPOUNDS AND METHODS OF USE THEREOF FOR TREATMENT OF HEALTH CONDITIONS AND DRUG SCREENING | REGLAGENE, INC. (US) | 2026-02-26 | — | — | WO | claimed |
| EP-3416626-B1 | MICROSPHERES FOR USE IN THERAPEUTIC EMBOLIZATION | BIOSPHERE MEDICAL INC (US) | 2026-02-25 | — | — | EP | claimed |
| US-12544350-B2 | Combinatorial antitumor treatment methods and related compositions, kits, and systems | KLOTHO THERAPEUTICS, INC. (US) | 2026-02-10 | — | — | US | claimed |
| US-12527818-B2 | Platinum-based chemotherapy, mast binding agents, glucocorticoid receptor (GR) binding agents, and/or HSP90 binding agents for uses in treating cancer | EMORY UNIVERSITY (US) | 2026-01-20 | — | — | US | claimed |
| EP-3706801-B1 | PLATINUM COMPLEXES AND USES THEREOF | L E A F HOLDINGS GROUP LLC (US) | 2026-01-14 | — | — | EP | claimed |
| CN-1861054-A | Composite slow-releasing anticarcinogen contg. platinum compounds such as sunpla | LANJIN BIOENGINEERING CO LTD S (CN) | 2006-11-15 | — | — | CN | claimed |
| CN-1861053-A | Slow-releasing injection contg. platinum compounds and cytotoxin type anticarcinogen | LANJIN BIOENGINEERING CO LTD S (CN) | 2006-11-15 | — | — | CN | claimed |
| CN-1861055-A | Composite slow-releasing anticarcinogen injection contg. platinum compounds | LANJIN BIOENGINEERING CO LTD S (CN) | 2006-11-15 | — | — | CN | claimed |
| CN-1861050-A | Anticancer drug sustained-release injection loaded with platinum compound and synergist thereof | LANJIN BIOENGINEERING CO LTD S (CN) | 2006-11-15 | — | — | CN | claimed |
| CN-1861052-A | Slow-releasing injection contg. platinum compound and cytotoxin type anticarcinogen | LANJIN BIOENGINEERING CO LTD S (CN) | 2006-11-15 | — | — | CN | claimed |
| CN-1861051-A | Slow-releasing injection contg. platinum compounds and its potentiator type anticarcinogen | LANJIN BIOENGINEERING CO LTD S (CN) | 2006-11-15 | — | — | CN | claimed |
| CN-1857221-A | Slow released anticancer medicien containing both platinum compound and its synergist | SHUAIHUA MEDICINE SCI TECH CO (CN) | 2006-11-08 | — | — | CN | claimed |
| WO-2006104668-A2 | COMPOSITION AND METHODS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2006-10-05 | — | — | WO | claimed |
| WO-2005112973-A1 | SENSITIZATION TO ANOTHER ANTICANCER THERAPY AND/OR AMELIORATION OF A SIDE EFFECT OF ANOTHER ANTICANCER THERAPY BY TREATMENT WITH A GST-ACTIVATED ANTICANCER COMPOUND | TELIK INC. (US) | 2005-12-01 | — | — | WO | claimed |
| US-20050261202-A1 | Sensitization to another anticancer therapy and/or amelioration of a side effect of another anitcancer therapy by treatment with a GST-activated anticancer compound | TELIK, INC. | 2005-11-24 | — | — | US | claimed |